{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:51:36Z","timestamp":1785167496572,"version":"3.55.0"},"reference-count":79,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"National Institute of Health NIH","award":["T32 DK-067872"],"award-info":[{"award-number":["T32 DK-067872"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.2217\/imt.12.85","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T17:44:10Z","timestamp":1349804650000},"page":"883-898","source":"Crossref","is-referenced-by-count":77,"title":["Vedolizumab for the Treatment of Ulcerative Colitis and Crohn\u2018s Disease"],"prefix":"10.1080","volume":"4","author":[{"given":"Leon P","family":"McLean","sequence":"first","affiliation":[{"name":"University of Maryland, Department of Medicine, Division of Gastroenterology & Hepatology, 100 North Greene Street, Lower Level, Baltimore, MD21201, USA"},{"name":"University of Maryland, Baltimore, Mucosal Biology Research Center, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terez","family":"Shea-Donohue","sequence":"additional","affiliation":[{"name":"University of Maryland, Department of Medicine, Division of Gastroenterology & Hepatology, 100 North Greene Street, Lower Level, Baltimore, MD21201, USA"},{"name":"University of Maryland, Baltimore, Mucosal Biology Research Center, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[{"name":"University of Maryland, Department of Medicine, Division of Gastroenterology & Hepatology, 100 North Greene Street, Lower Level, Baltimore, MD21201, USA"},{"name":"Veterans Affairs Maryland Health Care System, Baltimore, MD, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.063"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000195385.19268.68"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06005"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.5.696"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21488"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.012"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(08)60534-4"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20036"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822040-00005"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04612.x"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01589.x"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.019"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-8932(09)71035-8"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1869"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02742.x"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.024"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.451"},{"key":"e_1_3_2_3_23_1","unstructured":"TYSABRI\u00ae prescribing information. Biogen Idec Inc. MA USA (2012)."},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2011-000092"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"crossref","unstructured":"Milch C WyantT XuJ KentW BergerJ FoxI. Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. Presented at: 19th United European Gastroenterology Week. Stockholm Sweden 22\u201326 October 2011.","DOI":"10.14309\/00000434-201110002-01221"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/17.supplement1.S4b"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11405250"},{"key":"e_1_3_2_3_28_1","first-page":"CD003715","volume":"1","author":"Akobeng AK","year":"2005","unstructured":"Akobeng AK , GardenerE. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2018s Disease. Cochrane Database Syst. Rev.1 , CD003715 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(11)70575-8"},{"key":"e_1_3_2_3_30_1","first-page":"CD008870","volume":"12","author":"Lim WC","year":"2010","unstructured":"Lim WC , HanauerS. Aminosalicylates for induction of remission or response in Crohn\u2018s disease. Cochrane Database Syst. Rev.12 , CD008870 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90385-8"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04599.x"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01718.x"},{"key":"e_1_3_2_3_35_1","first-page":"CD003459","volume":"1","author":"Alfadhli AA","year":"2005","unstructured":"Alfadhli AA , McDonaldJW, FeaganBG. Methotrexate for induction of remission in refractory Crohn\u2018s disease. Cochrane Database Syst. Rev.1 , CD003459 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320503"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04073.x"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945011796818252"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00414-8"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.59"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04568.x"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03760.x"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099291"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301397"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90007-1"},{"issue":"1","key":"e_1_3_2_3_54_1","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.","volume":"151","author":"Briskin M","year":"1997","unstructured":"Briskin M , Winsor-HinesD, ShyjanA et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151(1) , 97\u2013110 (1997).","journal-title":"Am. J. Pathol."},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201110023"},{"issue":"4","key":"e_1_3_2_3_56_1","first-page":"311","volume":"22","year":"2008","unstructured":"WHO. International nonproprietary names for pharmaceutical substances. WHO Drug Information22(4) , 311\u2013367 (2008).","journal-title":"WHO Drug Information"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8898653"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042982"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21896"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.06.007"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60607-6"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13895"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(10)60667-1"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.40"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)85637-1"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-011-0104-6"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(11)60506-4"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60816-7"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.09.013"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.226548"},{"key":"e_1_3_2_4_2_1","unstructured":"Takeda Pharmaceutical Company Ltd. Takeda announces GEMINI II trial of vedolizumab in patients with moderately to severely active Crohn\u2018s disease met primary endpoints of improvement in clinical remission in induction and maintenance phases (2012). www.takeda.com\/press\/article_45691.html (Accessed 23August2012)"},{"key":"e_1_3_2_4_3_1","unstructured":"NIH. Study of vedolizumab (MLN0002) in patients with moderate to severe ulcerative colitis (GEMINI I). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00783718 (Accessed 20February2012)"},{"key":"e_1_3_2_4_4_1","unstructured":"NIH. Study of vedolizumab (MLN0002) in patients with moderate to severe Crohn\u2018s disease (GEMINI II). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00783692 (Accessed 20February2012)"},{"key":"e_1_3_2_4_5_1","unstructured":"NIH. Study of vedolizumab in patients with moderate to severe Crohn\u2018s diease (GEMINI III). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01224171 (Accessed 20February2012)"},{"key":"e_1_3_2_4_6_1","unstructured":"NIH. An open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn\u2018s diease (GEMINI LTS). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790933 (Accessed 20February2012)"},{"key":"e_1_3_2_4_7_1","unstructured":"NIH. Study to evaluate the long-term safety of rhumab beta7 in patients with moderate to severe ulcerative colitis. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01461317 (Accessed 7February2012)"},{"key":"e_1_3_2_4_8_1","unstructured":"WHO. Phase-IIa study of AJM300 in patients with active ulcerative colitis. http:\/\/apps.who.int\/trialsearch\/trial.aspx?trialid=JPRN-JapicCTI-090925 (Accessed 7February2012)"},{"key":"e_1_3_2_4_9_1","unstructured":"NIH. A study to investigate the efficacy and safety of gsk1605786a in the treatment of subjects with moderately-to-severely active Crohn\u2018s disease (SHIELD-1). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01277666 (Accessed 8February2012)"},{"key":"e_1_3_2_4_10_1","unstructured":"NIH. Study to test whether PF-00547659 is safe and improves disease symptoms in patients with Crohn\u2018s disease that have not responded to other treatments (OPERA). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01276509 (Accessed 8February2012)"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.12.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:06:04Z","timestamp":1715972764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.12.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.2217\/imt.12.85"],"URL":"https:\/\/doi.org\/10.2217\/imt.12.85","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}